80 results on '"Romagnoli, V."'
Search Results
2. Quantitative HBV/HDV markers help to distinguish different clinic/virologic phases of chronic hepatitis delta
3. HBsAg kinetics during and after nucleos(t)ide analogues described by mathematical modeling
4. OC.12.1 QUANTITATIVE HBV/HDV MARKERS HELP TO DISTINGUISH DIFFERENT CLINIC/VIROLOGIC PHASES OF CHRONIC HEPATITIS DELTA
5. Cancer cells and tumor vasculature dynamics analyzed by bio-mathematical modeling in HCC patients with different response to TKIs, TACE and TARE
6. Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients
7. AF.88 THREE HBSAG KINETIC PROFILES IN HBEAG NEGATIVE INFECTION AND CHRONIC HEPATITIS ARE ASSOCIATED WITH DIFFERENT CHANCES OF HBSAG CLEARANCE
8. OC.04.9 A SINGLE CENTER, LARGE LONG TERM COHORT STUDY OF THE RELATIONS BETWEEN MUTATIONS IN BASIC-CORE-PROMOTER AND PRE-C REGIONS OF HEPATITIS B VIRUS DNA AND CLINICPATHOLOGIC OUTCOME OF HBEAG-NEGATIVE/ANTI-HBEPOSITIVE PHASE
9. AF.89 CHANGING DEMOGRAPHIC-CLINIC-PATHOLOGIC PROFILES OF NEWLY DIAGNOSED CARRIERS OF CHRONIC HEPATITIS B VIRUS INFECTION ACROSS TWO DECADES: A SINGLE ITALIAN REFERENCE CENTER REPORT
10. AF.84 BIOIMAGING, BIOCHEMICAL AND GENETIC MARKERS TO STRATIFY PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN CLINICAL PRACTICE: A SINGLE CENTER COHORT STUDY
11. AF.96 MODELING HEPATOCELLULAR CARCINOMA CELLS DYNAMICS BY SEROLOGICAL AND IMAGING BIOMARKERS TO EXPLAIN COMPLETE RESPONSE TO SORAFENIB
12. Modeling hepatocellular carcinoma cells dynamics by serolo-gical and imaging biomarkers in patients with response to sorafenib and/or regorafenib
13. Changing demographic-clinic-pathologic profiles of newly diagnosed carriers of chronic hepatitis B virus infection across two decades: a single regional reference center report
14. A single center, large long-term cohort study of the relations between mutations in Basic-Core-Promoter and pre-C regions of Hepatitis B virus DNA and clinic-pathologic outcome of HBeAg-negative/anti-HBe-positive phase
15. T06.01.21 PNPLA3 COULD HELP THE CLINICIANS TO INDIVIDUATE NAFLD SUBJECTS AT MAJOR RISK OF DISEASE PROGRESSION: A SINGLE CENTER CHOHORT STUDY
16. T06.01.22 THREE HBSAG KINETIC PROFILES IN HBEAG NEGATIVE INFECTION AND CHRONIC HEPATITIS ARE ASSOCIATED WITH DIFFERENT CHANCES OF HBSAG CLEARANCE
17. HBsAg clearance in HBeAg negative infection and treated chronic hepatitis B is associated with different HBsAg kinetics
18. P.04.12 HBSAG SERUM LEVEL AND HBV GENE S QUASISPECIES IN THE HBEAG NEGATIVE PHASE OF CHRONIC GENOTYPE D HBV INFECTION
19. P.04.23 VERY LOWPREVALENCE OF ACTIVE HCV INFECTION AMONG HEALTHCARE WORKERS IN A REGIONAL REFERENCE HOSPITAL OF TUSCANY, ITALY
20. OC.01.6 THE CT1 MULTI-PARAMETRIC MRI VALUE IS MORE SENSITIVE AND RELIABLE THAN TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE MONITORING OF INTRA-HEPATIC INFLAMMATION/FIBROSIS RESPONSE TO DAA THERAPY IN CHC PATIENTS
21. Very low prevalence of active HCV infection among healthcare workers in a regional reference hospital of Tuscany, Italy
22. In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy
23. Low viremic HBeAg negative HBsAg carriers: Clinical outcome and non invasive diagnostic accuracy for chronic hepatitis B or inactive infection by combinations of HBV markers
24. In hepatitis C infected patients with cirrhosis squamous cell carcinoma antigen (SCCA)-IgM levels may contribute to identify the individual risk of hepatocellular carcinoma development after antiviral therapy
25. Low viremic HBeAg negative HBsAg carriers: clinical outcome and non invasive diagnostic accuracy for chronic hepatitis B or inactive infection by combinations of HBV markers
26. MiR-B-index: A candidate bio-marker to identify the immune control of HBV infection in chronic hepatitis B patients treated with nucleos(t)ide-analogues
27. Mir-B-Index: A Candidate Bio-Marker to Identify the Immune Control of HBV Infection in Chronic Hepatitis B Patients Treated with Nucleos(t)ide-Analogues
28. Aminosalicylates and pediatric UC: Use and efficacy at one year from diagnosis, results from the pediatric IBD Italian Registry
29. P0635 : Chronic hepatitis B treatment individualization by means of serum HBsAg and Mir-B-Index kinetics
30. Chronic hepatitis B treatment individualization by means of serum HBsAg and MiR-B-Index kinetics
31. P1202 EARLY PREDICTION OF SUSTAINED VIROLOGIC RESPONSE BY HCV CORE ANTIGEN KINETICS IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON PLUS RIBAVIRIN
32. P688 LONG-TERM OUTCOME OF INACTIVE AND LOW VIREMIC HBeAg NEGATIVE ACTIVE CARRIERS: BENIGN ONE DIRECTION TRANSITION TOWARDS SPONTANEOUS HBsAg CLEARANCE
33. P280 Anti glycoprotein-2 antibody in pediatric inflammatory bowel disease and celiac disease: prevalence, diagnostic value and variation at follow-up
34. Long-term outcome of inactive and low viremic HBeAg negative active carriers: Benign one direction transition towards spontaneous HBsAg clearance
35. Early prediction of sustained virologic response by HCV Core Ag kinetics in chronic hepatitis C patients treated with Peginterferon plus Ribavirin
36. Giant cell hepatitis and autoimmune hemolytic anemia: A 19 months follow-up
37. Glycoprotein 2 antibodies in adult and pediatric inflammatory bowel disease: Significance and correlations with phenotype
38. A case of NEC and multiple thromboses in a term baby: The role of thrombophilia
39. Intestinal stomas: A 4-year experience in a neonatal intensive care unit
40. Neonatal cholestasis in congenital syphilis
41. A complicated case of mesenteric cystic lymphangioma (MCL) with resulting short bowel syndrome
42. Intestinal anti-tissue transglutaminase IgA deposits in children with celiac disease: Significance and correlation with intestinal damage
43. HCV E1E 2‐ MF 59vaccine in chronic hepatitis C patients treated with PEG ‐ IFN α2a and R ibavirin: a randomized controlled trial
44. 632 AETIOLOGY OF CHRONIC LIVER DISEASE INFLUENCES CLINICAL PRESENTATION AND OUTCOME OF HEPATOCELLULAR CARCINOMA: A SINGLE CENTER COHORT STUDY
45. OC-25 Bio-mathematical modelling provides the most accurate selection of HCV-G1 patients for triple-therapy
46. T-06 Early HCV-Core-Ag kinetics predict sustained virologic response in chronic hepatitis C patients treated with standard of care
47. Information System and Systems Thinking: a Compulsory Marriage?
48. CO12 PHENOTYPE AND CLINICAL CHARACTERISTICS OF EARLY COMPARED TO LATE-ONSET PEDIATRIC INFLAMMATORY BOWEL DISEASE
49. CO36 INTESTINAL IgA ANTI-TISSUE TRANSGLUTAMINASE DEPOSITS IN PEDIATRIC CELIAC DISEASE
50. CO9 GLYCOPROTEIN 2 ANTIBODIES IN PEDIATRIC INFLAMMATORY BOWEL DISEASE: SIGNIFICANCE AND CORRELATIONS WITH THE PHENOTYPE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.